Short interest for Syntara gives investors a sense of the degree to which investors are betting on the decline of Syntara's stock. Short interest data is updated every two weeks.

Syntara Stock Short Interest Report | OTC:PMXSF | Benzinga

Syntara Ltd

Syntara

Overview

News

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring and neuroinflammation.

Comments

Syntara Short Interest Report

Syntara Stock Short Interest Report | OTC:PMXSF | Benzinga